Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Cantharidin

    Client Email Product
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Cantharidin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Verrica Announces Positive Topline Results From Phase 2 Study Of VP-315 For BCC
    Verrica Announces Positive Topline Results From Phase 2 Study Of VP-315 For BCC

    14 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/14/2929965/0/en/Verrica-Pharmaceuticals-Announces-Positive-Preliminary-Topline-Results-from-Part-2-of-Phase-2-Clinical-Study-of-VP-315-an-Investigational-Oncolytic-Peptide-Based-Immunotherapy-for-.html

    GLOBENEWSWIRE
    14 Aug 2024
    Share Share
    Verrica Announces that YCANTH Receives New Chemical Entity Status
    Verrica Announces that YCANTH Receives New Chemical Entity Status

    26 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/26/2852256/0/en/Verrica-Pharmaceuticals-Announces-that-YCANTH-Receives-New-Chemical-Entity-Status-and-Orange-Book-Listing-from-the-FDA.html

    GLOBENEWSWIRE
    26 Mar 2024
    Share Share
    Verrica Pharma to Host Virtual KOL Event Discussing the Approval of YCANTH
    Verrica Pharma to Host Virtual KOL Event Discussing the Approval of YCANTH

    27 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/27/2750291/0/en/Verrica-Pharmaceuticals-to-Host-Virtual-KOL-Event-Discussing-the-Approval-of-YCANTH-Cantharidin-Topical-Solution-for-the-Treatment-of-Molluscum-on-October-11-2023.html

    GLOBENEWSWIRE
    27 Sep 2023
    Share Share
    FDA approves Verrica's skin infection treatment, enters into non-binding term sheet for $125M loan
    FDA approves Verrica's skin infection treatment, enters into non-binding term sheet for $125M loan

    24 Jul 2023

    // Lia DeGroot ENDPTS

    https://endpts.com/fda-approves-verricas-skin-infection-treatment-enters-into-non-binding-term-sheet-for-125m-loan/

    Lia DeGroot ENDPTS
    24 Jul 2023
    Share Share
    Verrica's drug gets US nod as first treatment for a type of skin infection
    Verrica's drug gets US nod as first treatment for a type of skin infection

    22 Jul 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-verricas-skin-disease-treatment-2023-07-21/

    REUTERS
    22 Jul 2023
    Share Share
    JAMA Dermatology Publishes Results from Verrica’s Pivotal Phase III CAMP Trials
    JAMA Dermatology Publishes Results from Verrica’s Pivotal Phase III CAMP Trials

    23 Sep 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/09/23/2098298/0/en/JAMA-Dermatology-Publishes-Results-from-Verrica-s-Two-Pivotal-Phase-III-CAMP-Cantharidin-Application-in-Molluscum-Patients-Trials.html

    GLOBENEWSWIRE
    23 Sep 2020
    Share Share